STUB1 and myelodysplastic syndrome: Several studies have demonstrated that CHIP can be a precursor to MDS and AML, in particular after cytotoxic therapy, suggesting that such treatments promote the emergence and expansion of mutated cells, thereby increasing the risk of leukemic transformation.